Skip to main content
. Author manuscript; available in PMC: 2014 Dec 28.
Published in final edited form as: J Control Release. 2013 Oct 12;172(3):10.1016/j.jconrel.2013.10.008. doi: 10.1016/j.jconrel.2013.10.008

Fig. 2.

Fig. 2

DXR-PSA-PEG3 nanoparticles inhibit choroidal and retinal NV.

After laser-induced rupture of Bruch’s membrane in 3 locations, C57BL/6 mice received DXR-PSA-PEG3 0.65 μm particles (1 μg DXR content) via an intravitreal injection. Between 1 and 14 days after injection the nanoparticles were seen as orange aggregates (A, Day 1, B, Day 7, C, Day 14, arrows) in the posterior vitreous in front of the optic nerve (ON). Areas of laser photocoagulation are also visible (white arrowheads). The area of choroidal NV at Bruch’s membrane rupture sites appeared smaller in eyes injected with DXR-PSA- PEG3 nanoparticles (D) compared to those injected with PBS (E) and image analysis showed a significant reduction in mean area of choroidal NV in eyes injected with DXR-PSA- PEG3 nanoparticles (0.1, 1.0, or 10 μg DXR content) compared to fellow eyes injected with PBS (F). At P12, mice with oxygen-induced ischemic retinopathy received DXR-PSA-PEG3 nanoparticles (1 μg DXR content) in one eye and PBS in the fellow eye and at P17, there was a significant reduction in retinal NV in the former (G–I).